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Abstract
Fused in sarcoma (FUS) or translocation in liposarcoma (TLS), a DNA/RNA-binding protein, causes a dominant autosomal inherited form
of amyotrophic lateral sclerosis (ALS), ALS 6. Its main role in neurodegeneration is highlighted by the presence of cytoplasmic
accumulation of its mutant protein form in ALS patients. To further define the frequency and spectrum of FUS gene mutations, we have
performed a molecular screening of a cohort of 327 Italian patients from Southern Italy with sporadic ALS (SALS). We identified 4 patients
carrying 3 different missense mutations and several polymorphisms. Two different substitutions occurring in the same amino acidic position
have been observed in 2 patients: R521G and R521C respectively; P525L mutation has been found in 2 additional cases. Most of the patients
with FUS mutations showed early symptom onset and had short disease survival. We also detected 4 different polymorphic variants
(3=-untranslated region [UTR] variant, c.*41G.A; c.52313ins[GAGGTG]; c.335-15del[TTTT]; and rs13331793) in 9 patients from within
our cohort. This study underlines the importance of population-based mutation screening of newly identified genes.
© 2011 Elsevier Inc. All rights reserved.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset
neurodegenerative disorder characterized by the loss of up-
per and lower motor neurons, resulting in progressive mus-
cle weakness and atrophy, which causes death within 3 to 5
years from symptom onset.
In the last decade several genes implicated in the RNA
processing pathways have been associated with ALS, in-
cluding the fused in sarcoma/traslocated in liposarcoma
gene (FUS/TLS) (Strong, 2010). FUS is a ubiquitously ex-
pressed 526 amino acid protein, encoded by 15 exons, that
belongs to the FET/TET family (FUS, EWS and TAF15
proto-oncoproteins) of multifunctional DNA/RNA binding
proteins. FUS contains an N-terminal Gln-Gly-Ser-Tyr-rich
domain, a Gly-rich domain, an RNA recognition motif,
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multiple Arg-Gly-Gly repeats, a zinc-finger motif and a
highly conserved extreme C-terminus that encodes a non-
classic nuclear localization signal (NLS), recognized by
transportin (Mackenzie et al., 2010).
Mutations in the FUS gene have been identified as the
primary cause of ALS 6, an autosomal dominant form of
familial ALS (FALS) linked to chromosome 16. The only
exception is the Cape Verdean family for which the FUS
mutation (p. H517Q) causes ALS only in a homozygous
state (Lagier-Tourenne and Cleveland, 2009).
Subsequent reports of FUS mutations have also been
described in sporadic patients (Talbot, 2009).
Much evidence suggests that mutations in FUS are as-
sociated with earlier onset of ALS than the general mean
age of approximately 60 years (Corrado et al., 2010; Kwi-
atkowski et al., 2009; Vance et al., 2009).
In most cell types, FUS is present in both the nucleus and
cytoplasm, but in neurons the proportion of FUS is higher in
the nucleus than in the cytoplasm and in glia FUS is exclu-
sively nuclear (Neumann et al., 2009). Neuropathological
analysis of brain and spinal cord of ALS patients carrying
mutations showed cytoplasmic retention and the formation
of FUS ubiquitin-positive neuronal aggregates (DeJesus-
Hernandez et al., 2010).
In only 2 years, 35 different pathogenic FUS mutations
have been identified; they account for about 4% of familial
ALS cases, but less than 1% of sporadic ALS cases. Most of
these mutations (21 missense mutations) are clustered in the
NLS region (encoded by exons 14 and 15) and may exert
their pathogenic effects by disrupting the subcellular distri-
bution of the protein, assuming a toxic gain of function
effect (Hewitt et al., 2010; Mackenzie et al., 2010).
In this study, in order to investigate the presence and
frequency of FUS mutations in our cohort of south Italian
ALS patients, we performed a mutational screening of the
FUS gene in 327 SOD1-negative, ANG-negative, VAPB-
negative, and TARDBP-negative sporadic ALS (SALS)
cases. We also wished to report the clinical findings of those
ALS patients carrying FUS mutations.
2. Methods
2.1. Patients
A total of 327 unrelated Caucasian patients from south-
ern Italy (185 men and 142 women; mean age at onset 56.5
years, SD 12.2381) were included in this study. Each patient
underwent a full neurological evaluation including electro-
myography, clinical laboratory testing, and imaging as ap-
propriate to establish the clinical diagnosis of ALS accord-
ing to the El Escorial criteria (Brooks et al., 2000). Patients
were classified as sporadic when none of them had a known
family history of ALS. Age at onset, gender distribution,
site of symptom onset (bulbar and/or spinal-onset), predom-
inance of upper/lower motor neuron signs, and disease du-
ration were recorded (Table 1). Mini Mental State Exami-
nation (MMSE), Frontal Assessment Battery (FAB) and
Beck Depression Inventory were administered in FUS mu-
tation carriers to evaluate general and severe cognitive de-
terioration, frontal cognitive impairment, and severe depres-
sion, respectively.
All patients tested negative for mutations in SOD1, ANG,
VAPB, and TARDBP genes.
Control DNA was obtained from 100 unrelated, ethni-
cally matched unaffected subjects with a negative personal
and familial history for neurodegenerative diseases. In-
formed written consent was obtained from each individual,
and appropriate institutional review board approval was
obtained concerning human subjects. Blood samples were
collected and DNA was extracted using standard protocols.
2.2. Molecular analysis
Until now, the previously reported variants, predicting an
amino acid change, were all located in exons 3, 5, 6, 12, 14,
and 15, which are the only FUS regions affected by muta-
tions in ALS patients; therefore, we specifically screened
these exons in 327 SALS patients. Twelve primer pairs were
designed from genomic DNA to amplify, by polymerase
chain reaction (PCR), 6 coding exons and relative intron/
exon boundaries of the FUS gene. The amplicons for exons
3, 5, 6, 12, and 14 were analyzed by denaturing high-
performance liquid chromatography (DHPLC) (Wave
Transgenomic, Mountain View, CA, USA), while exon 15
was amplified and directly sequenced in each individual
using the BigDye terminator v3.1 sequencing chemistry
(Applied Biosystems, Foster City, CA, USA) and run on an
ABI PRISM 3130 Genetic Analyzer (Applied Biosystem).
In each case, forward primer or reverse primer was used for
sequencing and variations were confirmed by sequencing an
independent polymerase chain reaction product. Nucleotide
numbering of FUS variations reflects cDNA numbering
with 11 corresponding to the A of the ATG translation
initiation codon reported in the GenBank reference se-
quence NM_004960.2, according to the journal guidelines
(www.hgvs.org/mutnomen/). The initiation codon is codon 1.
Table 1
Clinical and genetic details of amyotrophic lateral sclerosis (ALS)
patients
Sporadic ALS cases n 5 327
Mean age at onset, y 56.55
Male (%) 185 (56.6)
Female (%) 142 (43.4)
Site of symptom onset (%)a
Bulbar-onset disease 55 (17.2)
Spinal-onset disease 261 (81.6)
Lower 125 (47.9)
Upper 122 (46.7)
Mean disease duration (mo)b 42.03
SOD1-, VAPB-, ANG-, TARDBP-positive None
a Site of symptom onset data were not available for 7 cases.
b Disease duration data were not available for 40 cases.
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2.3. Statistical analysis
Statistical differences between SALS patients carrying
FUS mutations and the whole ALS cohort were evaluated.
In particular, because the expected frequencies were low,
Fisher exact test and Monte Carlo method were used to
compare gender distribution and site of onset, respectively.
Age at onset and disease duration were evaluated using
Mann–Whitney U test.
3. Results
Molecular screening of the exons 3, 5, 6, 12, 14, and 15
of the FUS gene showed 3 different missense mutations in
4/327 SALS patients (Table 2). Two different substitutions
occurring in the same amino acidic position have been
observed in 2 patients: R521G and R521C respectively;
P525L mutation has been found in 2 additional cases. All
the observed mutations were found in exon 15 of the FUS
gene and have been previously reported (Kwiatkowski et
al., 2009; Ticozzi et al., 2009; Vance et al., 2009).
The mean of age at onset in these patients (38.75 years)
was lower than in the whole cohort (56.77 years), and this
difference is statistically significant (Mann-Whitney U test,
p 5 0.016). In all cases, except 1, symptoms onset was
before 50 years of age.
The neurological examination of the 4 FUS mutation
carriers showed a muscle atrophy of the upper and lower
limbs. Three out of the 4 FUS carriers also showed upper
motor neuron signs. Electromyograms (EMGs) showed
denervation in multiple myotomes of the upper and lower
limbs, where motor unit potentials (MUPs) were polyphasic
and increased in number and duration. Fibrillation poten-
tials and fasciculations were also recorded. Motor and sen-
sory conduction studies were within normal ranges. Cere-
brospinal fluid analysis, levels of vitamins, thyroid function,
and immunoelectrophoresis were normal. Brain and spine
magnetic resonance imaging (MRI) scans were normal.
None of the patients in this study showed signs of cognitive
impairment, and all cases but 1 (ALS-03) showed a site of
onset in the upper limb.
In detail, the patient carrying the R521C mutation (ALS-
01) was a 55-year-old married woman, who presented a
2-year history of progressive weakness and atrophy of the
proximal muscles of the right upper limb. Her past medical
history was negative. Her parents were not consanguineous.
A clinical diagnosis of spinal-onset ALS was made. As the
respiratory function progressively deteriorated, she under-
went a tracheostomy. A few years later, the patient died of
acute renal failure.
The patient carrying the R521G mutation (ALS-02) is a
34-year-old man who experienced onset at age 32. He
showed predominantly upper motor neuron signs with fas-
ciculations and onset in the upper limbs. His parents were
not available for the study. The patient is still alive.
One of the patients carrying the P525L mutation (ALS-
03) was a 26-year-old man, who had a 7-month history of
progressive weakness and wasting. Weakness began in the
lower limbs and progressed to the muscles of the upper
limbs 5 months later. His past medical history was negative.
His parents were not consanguineous and were not available
for the study. A clinical diagnosis of lower motoneuron
disease was made. One month later the patient died of acute
cardiorespiratory failure.
The other patient carrying the P525L mutation (ALS-04)
was a 45-year-old woman affected by multiple sclerosis
with predominantly cerebellar and sensory disturbances,
confirmed by neuroradiological and neuroimmunological
investigations (intrathecal oligoclonal IgG synthesis). The
patient developed a progressive weakness at the upper limbs
(prominently at the left side) with diffuse fasciculations,
intrinsic hand-muscle hypotrophy, followed by dysphagia,
dysphonia, and progressive weakness of the 4 limbs. A
diagnosis of ALS was made based on clinical and electro-
physiological criteria. The patient underwent percutaneous
endoscopic gastrostomy (PEG), and she died of respiratory
failure 42 months after the onset of the disorder.
In our screening, we also found 4 different known
polymorphic variants in 9 cases (Corrado et al., 2010;
Ticozzi et al., 2009). In 6 patients we detected the 3=-
untranslated region (UTR) variant, c.*41G.A, and in no
cases was familial history of the disease recorded. We identi-
fied the variation c.1393134G.T (rs13331793) in 1 female
patient, who was diagnosed at 49 years of age with definite
sporadic ALS, and the variation c.521_52313delGAGGTG in
the P525L-carrier patient described above (ALS-03). The
known intronic variation c.335-15 del[TTTT] was detected
in 1 previously described male patient (Conforti et al.,
2004). Two of the above-mentioned polymorphic variants,
c.*41G.A and c.335-15 del[TTTT], were also observed in
our control subjects with a frequency of 0.3% and 0.1%,
respectively.
Table 2
Clinical characteristics of FUS mutation carriers
Patient ALS-01 ALS-02 ALS-03 ALS-04
Mutation R521C R521G P525L P525L
Exon 15 15 15 15
Gender F M M F
Age of onset, y 53 32 26 45
Death Yes No Yes Yes
Disease duration
(mo)
60 27 13 42











No No No No
Bulbar signs No Yes Yes Yes
UMN signs Yes Yes No Yes
LMN signs Yes Yes Yes Yes
Key: F, female; LMN, lower motor neuron; M, male, UMN, upper motor
neuron.
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4. Discussion
In the current study, we reported a molecular screening
of the FUS/TLS gene in 327 sporadic ALS patients from
southern Italy. We detected 3 different missense mutations
in 4 sporadic ALS cases (p. R521C, p. R521G, p. P525L)
with a frequency of 1.25%, which is slightly higher than
what has been previously reported (Belzil et al., 2009;
Corrado et al., 2010; Ticozzi et al., 2009). However, all
patients must be considered apparently sporadic because
either there was no family member DNA available for
testing or there was a lack of information about the patients’
family trees.
Regarding the clinical characteristics of the 4 FUS mu-
tated patients (Table 2), the mean age at onset in these ALS
patients was significantly lower (38.75 years) than in the
whole cohort (56.78). This result confirms that mutations in
FUS are associated with an earlier onset of the disease in
comparison with the general mean age of approximately 60
years reported for ALS (Corrado et al., 2010).
None of the patients in this study showed signs of cog-
nitive impairment. Approximately 5% of patients with ALS
also develop frontotemporal dementia (Groen et al., 2010),
and to date only a small number of ALS/dementia patients
with FUS mutations have been described, but it seems
that cognitive dysfunction is absent or rare in FUS-
mediated ALS (Blair et al., 2009; Groen et al., 2010;
Lagier-Tourenne and Cleveland, 2009; Ticozzi et al.,
2009; Yan et al., 2010).
The mutations p.R521C and p.R521G were observed in
2 sporadic ALS cases (ALS-01, ALS-02) without an appar-
ent family history of motoneuron disease. The arginine at
codon 521 is preserved during evolution, and it represents
the most commonly mutated amino acid, identified in 11
families and in 2 sporadic cases (Rademakers et al., 2010).
Both amino acid substitutions disrupt the NLS and lead to
an aberrant subcellular distribution of FUS protein, with
retention in the cytoplasm. In literature, the mutation
R521G has been described with a reduced penetrance of the
disease (Kwiatkowski et al., 2009); while mutation R521C
has been associated with complete penetrance (Corrado et
al., 2010). Even if both of these mutations occur in the same
codon position and possibly cause the same cellular dam-
age, patients ALS-01 (R521G carrier) and ALS-02 (R521C
carrier) showed different clinical pictures for age of onset
and disease course. Indeed, patient ALS-01 had an onset at
53 years and showed a survival duration that was much
longer than ALS-02 patient (Table 2). The patient carrying
the p.R521C mutation showed a clinical phenotype similar
to that already described in Italian patients (Corrado et al.,
2010; Ticozzi et al., 2009). This confirms the possibility to
associate specific phenotypes with some FUS mutations,
even if the identification of additional patients carrying the
same mutation should provide more insight into the geno-
type-phenotype correlations.
The mutation p.P525L, which also localized in exon 15
of the gene, was detected in 2 SALS patients (ALS-03 and
ALS-04). All previously described p.P525L mutation carri-
ers showed an aggressive course of the disease and no
family history has been documented in any previous studies
(Bäumer et al., 2010; Chiò et al., 2009; Kwiatkowski et al.,
2009). The clinical pattern observed in patient ALS-03
(young age at onset at 26 years and rapid progression
causing death within 12 months), is similar to that already
reported for this mutation, confirming that the p.P525L
substitution results in a highly aggressive form of ALS.
Unfortunately, DNA samples from the unaffected parents
were not available, and this patient must be considered
apparently sporadic as well. Furthermore, this patient car-
ried both the P525L mutation and the known variation
c.521_52313delGAGGTG in exon5. This deletion was first
reported as a pathogenic mutation in FALS patients (Kwi-
atkowski et al., 2009) and was also detected in healthy
subjects (Rademakers et al., 2010). These findings, together
with our data further suggest that it does not represent a
pathogenic mutation.
Instead, a different course of the disease was observed in
the other p.P525L carrier, ALS-04, who showed a demyeli-
nating disease associated with SALS. The pathological ev-
idence of both ALS and multiple sclerosis in a FUS muta-
tion carrier was also reported in a British familial ALS
patient (Hewitt et al., 2010). In our patient, the demyelinat-
ing disease was already present at the age of 45, when ALS
symptoms arose and led to death of the patient after 42
months, a much longer period of time than any other case
described. Obviously, the onset variability and survival du-
ration seen in the patients carrying the same mutation, could
be attributed to additional genetic and/or environmental
factors, which could modify the penetrance of the disease.
In conclusion, in our cohort of 327 SALS patients we
detected 4 FUS mutations, representing 1.25% of SALS
cases, and the occurrence of several polymorphisms. More-
over, although our data illustrates that patients with FUS
mutations may develop either classic or atypical ALS phe-
notypes, it seems that most patients predominantly demon-
strate earlier symptom onset and short disease survival (Yan
et al., 2010). Furthermore, this study highlights the impor-
tance of population-based mutation screening of newly
identified genes, such as FUS, as a starting point for inves-
tigating the pathogenic mechanism leading to ALS.
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